Distal Protection Combined With PTCA in AMI Patients (DIPLOMAT)
Distal Protection Combined With PTCA in AMI Patients -- The DIPLOMAT Study.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Massy, France, F - 91300
- Institut Cardiovasculaire Paris Sud
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Acute myocardial infarction < 12 hours with ST segment elevation > 2 mm in at least 2 contiguous leads;
- Clinical indication of primary PTCA;
- De novo or restenotic lesions in native coronary vessel, single vessel treatment only;
- Target lesion stenosis is > 80% (by visual estimation).
Exclusion Criteria:
- Patient has unprotected left main coronary disease with > 50% stenosis in case left coronary artery is treated;
- Patient has an ostial target lesion;
- Killip class > 3.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: 1
PTCA
|
PTCA
|
|
Other: 2
PTCA with angioguard
|
PTCA with the Angioguard distal protection device.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Absolute ST segment resolution.
Time Frame: post-PTCA
|
post-PTCA
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
ST segment resolution (> 50% decrease).
Time Frame: pre- and post-PTCA
|
pre- and post-PTCA
|
|
TIMI Frame Count
Time Frame: post PTCA
|
post PTCA
|
|
Composite endpoint of slow flow, no reflow or distal embolization.
Time Frame: at anytime
|
at anytime
|
|
Regional wall motion index by echocardiography.
Time Frame: discharge and 6 month follow-up
|
discharge and 6 month follow-up
|
|
Clinical success evaluation; qualitative evaluation of device and delivery system characteristics.
Time Frame: post-procedure
|
post-procedure
|
|
Cardiac function assessed by echocardiography.
Time Frame: before discharge and at 6 month follow-up
|
before discharge and at 6 month follow-up
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Thierry LEFEVRE, MD, Hopital Tarnier-Cochin
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- EC00-02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.